SCHEMBL5739367

SCHEMBL5739367

CN(C)CCSc1ccc(C(O)(c2ccccc2)C(CCOC2CCCCO2)c2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.36
KMT2A Q03164 7/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 2/20 0.35
CHRM2 P08172 2/20 0.34
CHRM4 P08173 2/20 0.34
CHRM1 P11229 2/20 0.34
CHRM3 P20309 2/20 0.34
KDM4C Q9H3R0 1/20 0.33
SERPINE1 P05121 1/20 0.32
TTR P02766 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
SLC6A3 Q01959 2/20 0.31
SLC6A4 P31645 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9860185 0.86 MEN1 (0.46) MEN1KMT2APOLBKDM4CSLC6A3
SCHEMBL5724868 0.85 MEN1 (0.35) MEN1KMT2APOLBCHRM2CHRM1
SCHEMBL9860242 0.83 MEN1 (0.46) MEN1KMT2APOLBKDM4CSLC6A3
SCHEMBL5726588 0.82 MEN1 (0.41) MEN1KMT2AALDH1A1POLBKDM4C
SCHEMBL9860239 0.80 MEN1 (0.43) MEN1KMT2APOLBKDM4CADORA3
SCHEMBL10923422 0.76 MEN1 (0.47) MEN1KMT2APOLBKDM4CSLC6A3
SCHEMBL10827794 0.75 MEN1 (0.42) MEN1KMT2AALDH1A1POLBCHRM2
SCHEMBL5728082 0.75 SERPINE1 (0.37) MEN1KMT2AALDH1A1POLBCHRM2
SCHEMBL10807959 0.74 MEN1 (0.38) MEN1KMT2APOLBKDM4CNPC1
SCHEMBL9622131 0.73 MEN1 (0.42) MEN1KMT2AALDH1A1POLBCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP disclosed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 MEN1 3414/4885KMT2A 987/4885ALDH1A1 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.